Effect of Vorapaxar Alone and in Combination with Aspirin on Bleeding Time and Platelet Aggregation in Healthy Adult Subjects

W. K. Kraft, J. H. Gilmartin, D. L. Chappell, F. Gheyas, B. M. Walker, S. Nagalla, U. P. Naik, J. C. Horrow, R. E. Wrishko, S. Zhang, M. S. Anderson

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The effect of the protease-activated receptor-1 (PAR-1) antagonist vorapaxar on human bleeding time is not known. This was a randomized, two-period, open-label trial in healthy men (n = 31) and women (n = 5). In period 1, subjects received 81 mg aspirin q.d. or a vorapaxar regimen achieving steady-state plasma concentrations equivalent to chronic 2.5 mg q.d. doses, for 7 days. In period 2, each group added 7 days of the therapy alternate to that of period 1 without washout. Bleeding time and platelet aggregation using arachidonic acid, ADP, and TRAP agonists were assessed. Bleeding time geometric mean ratio (90% CI) for vorapaxar/baseline was 1.01 (0.88–1.15), aspirin/baseline was 1.32 (1.15–1.51), vorapaxar + aspirin/vorapaxar was 1.47 (1.26–1.70), and vorapaxar + aspirin/aspirin was 1.12 (0.96–1.30). Unlike aspirin, vorapaxar did not prolong bleeding time compared with baseline. Bleeding time following administration of vorapaxar with aspirin was similar to that following aspirin alone.

Original languageEnglish (US)
Pages (from-to)221-227
Number of pages7
JournalClinical and Translational Science
Volume9
Issue number4
DOIs
StatePublished - Aug 1 2016

Fingerprint

Bleeding Time
Platelets
Platelet Aggregation
Aspirin
Healthy Volunteers
Agglomeration
PAR-1 Receptor
vorapaxar
Arachidonic Acid
Adenosine Diphosphate
Labels
Plasmas

ASJC Scopus subject areas

  • Neuroscience(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Effect of Vorapaxar Alone and in Combination with Aspirin on Bleeding Time and Platelet Aggregation in Healthy Adult Subjects. / Kraft, W. K.; Gilmartin, J. H.; Chappell, D. L.; Gheyas, F.; Walker, B. M.; Nagalla, S.; Naik, U. P.; Horrow, J. C.; Wrishko, R. E.; Zhang, S.; Anderson, M. S.

In: Clinical and Translational Science, Vol. 9, No. 4, 01.08.2016, p. 221-227.

Research output: Contribution to journalArticle

Kraft, WK, Gilmartin, JH, Chappell, DL, Gheyas, F, Walker, BM, Nagalla, S, Naik, UP, Horrow, JC, Wrishko, RE, Zhang, S & Anderson, MS 2016, 'Effect of Vorapaxar Alone and in Combination with Aspirin on Bleeding Time and Platelet Aggregation in Healthy Adult Subjects', Clinical and Translational Science, vol. 9, no. 4, pp. 221-227. https://doi.org/10.1111/cts.12405
Kraft, W. K. ; Gilmartin, J. H. ; Chappell, D. L. ; Gheyas, F. ; Walker, B. M. ; Nagalla, S. ; Naik, U. P. ; Horrow, J. C. ; Wrishko, R. E. ; Zhang, S. ; Anderson, M. S. / Effect of Vorapaxar Alone and in Combination with Aspirin on Bleeding Time and Platelet Aggregation in Healthy Adult Subjects. In: Clinical and Translational Science. 2016 ; Vol. 9, No. 4. pp. 221-227.
@article{9e1544c7b8b4446aba9c07e37f5197de,
title = "Effect of Vorapaxar Alone and in Combination with Aspirin on Bleeding Time and Platelet Aggregation in Healthy Adult Subjects",
abstract = "The effect of the protease-activated receptor-1 (PAR-1) antagonist vorapaxar on human bleeding time is not known. This was a randomized, two-period, open-label trial in healthy men (n = 31) and women (n = 5). In period 1, subjects received 81 mg aspirin q.d. or a vorapaxar regimen achieving steady-state plasma concentrations equivalent to chronic 2.5 mg q.d. doses, for 7 days. In period 2, each group added 7 days of the therapy alternate to that of period 1 without washout. Bleeding time and platelet aggregation using arachidonic acid, ADP, and TRAP agonists were assessed. Bleeding time geometric mean ratio (90{\%} CI) for vorapaxar/baseline was 1.01 (0.88–1.15), aspirin/baseline was 1.32 (1.15–1.51), vorapaxar + aspirin/vorapaxar was 1.47 (1.26–1.70), and vorapaxar + aspirin/aspirin was 1.12 (0.96–1.30). Unlike aspirin, vorapaxar did not prolong bleeding time compared with baseline. Bleeding time following administration of vorapaxar with aspirin was similar to that following aspirin alone.",
author = "Kraft, {W. K.} and Gilmartin, {J. H.} and Chappell, {D. L.} and F. Gheyas and Walker, {B. M.} and S. Nagalla and Naik, {U. P.} and Horrow, {J. C.} and Wrishko, {R. E.} and S. Zhang and Anderson, {M. S.}",
year = "2016",
month = "8",
day = "1",
doi = "10.1111/cts.12405",
language = "English (US)",
volume = "9",
pages = "221--227",
journal = "Clinical and Translational Science",
issn = "1752-8054",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Effect of Vorapaxar Alone and in Combination with Aspirin on Bleeding Time and Platelet Aggregation in Healthy Adult Subjects

AU - Kraft, W. K.

AU - Gilmartin, J. H.

AU - Chappell, D. L.

AU - Gheyas, F.

AU - Walker, B. M.

AU - Nagalla, S.

AU - Naik, U. P.

AU - Horrow, J. C.

AU - Wrishko, R. E.

AU - Zhang, S.

AU - Anderson, M. S.

PY - 2016/8/1

Y1 - 2016/8/1

N2 - The effect of the protease-activated receptor-1 (PAR-1) antagonist vorapaxar on human bleeding time is not known. This was a randomized, two-period, open-label trial in healthy men (n = 31) and women (n = 5). In period 1, subjects received 81 mg aspirin q.d. or a vorapaxar regimen achieving steady-state plasma concentrations equivalent to chronic 2.5 mg q.d. doses, for 7 days. In period 2, each group added 7 days of the therapy alternate to that of period 1 without washout. Bleeding time and platelet aggregation using arachidonic acid, ADP, and TRAP agonists were assessed. Bleeding time geometric mean ratio (90% CI) for vorapaxar/baseline was 1.01 (0.88–1.15), aspirin/baseline was 1.32 (1.15–1.51), vorapaxar + aspirin/vorapaxar was 1.47 (1.26–1.70), and vorapaxar + aspirin/aspirin was 1.12 (0.96–1.30). Unlike aspirin, vorapaxar did not prolong bleeding time compared with baseline. Bleeding time following administration of vorapaxar with aspirin was similar to that following aspirin alone.

AB - The effect of the protease-activated receptor-1 (PAR-1) antagonist vorapaxar on human bleeding time is not known. This was a randomized, two-period, open-label trial in healthy men (n = 31) and women (n = 5). In period 1, subjects received 81 mg aspirin q.d. or a vorapaxar regimen achieving steady-state plasma concentrations equivalent to chronic 2.5 mg q.d. doses, for 7 days. In period 2, each group added 7 days of the therapy alternate to that of period 1 without washout. Bleeding time and platelet aggregation using arachidonic acid, ADP, and TRAP agonists were assessed. Bleeding time geometric mean ratio (90% CI) for vorapaxar/baseline was 1.01 (0.88–1.15), aspirin/baseline was 1.32 (1.15–1.51), vorapaxar + aspirin/vorapaxar was 1.47 (1.26–1.70), and vorapaxar + aspirin/aspirin was 1.12 (0.96–1.30). Unlike aspirin, vorapaxar did not prolong bleeding time compared with baseline. Bleeding time following administration of vorapaxar with aspirin was similar to that following aspirin alone.

UR - http://www.scopus.com/inward/record.url?scp=84982239073&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982239073&partnerID=8YFLogxK

U2 - 10.1111/cts.12405

DO - 10.1111/cts.12405

M3 - Article

VL - 9

SP - 221

EP - 227

JO - Clinical and Translational Science

JF - Clinical and Translational Science

SN - 1752-8054

IS - 4

ER -